Member Info for Laura2022

Lot more advanced now than then AND funded till 2028 unlike then

:)))))

P140 partnering discussions

As reiterated in recent announcements, P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value‑enhancing licensing deal in 2026.

Looking stronger again

Publications support p140

Deals in 2026

Another controlling interest stitch up

Five lupus patients in England are in remission after being treated with a revolutionary therapy that genetically modifies their own cells, in a medical breakthrough that could offer people a cure, doctors have said.

CAR (chimeric antigen receptor) T-cell therapy involves removing a type of white blood cell also called T lymphocytes, which are crucial for hunting out infected or damaged cells, and engineering them to spot and destroy disease. The T-cells are then fed back into the patient via an infusion to reset their immune system.

The therapy is already revolutionising cancer treatment

Fantastic news

Fallen 3p to 0 9p

Maybe the green boxes can tune in

its live interactive presentation via Engage Investor, initially scheduled for later today, will now take place at 14:30 BST on Tuesday 16th June 2026. The presentation will be delivered by the Company's CEO, Paul Reeves, and CFO, Rob Shepherd.

 

Should go quickly this morning

The global media campaign and public exhibitions achieved over the last two months have fundamentally proven the market appeal of "Extinction is the new black" and supercharged active, high-level corporate pipeline discussions with multi-billion-dollar Tier-1 companies:

Bid is ABOVE 1p

No where near 0.75 lol

Ive added jvip

Then don't buy

Bounce hard

Reckon that 10-15mln is seller cleared

May even by RE

WW

So much disinformation from non holders I assime ?

Jeres the facts

The structure of the Lanstead subscription provides a mechanism through which the Company may potentially benefit from future share price performance, with the 8p Benchmark Price acting as the reference point for returns under the Sharing Arrangement. The Board therefore believes that continued operational progress and news flow relating

P140 and Kapiglucagon, have the potential to support value creation over the period of the agreement.

Off topic

Anyone know abiut PACS ?

Richard edwards shell £200k cap !

Under £200k ?

£57k trade

14%

Rodney

Welcome

Just to clarify I'm not sure who that Insta account is as I dont use Instagram

Best wishes

Momentun to have continued after the record ever revenues mentioned before via RNS amd also more on Pete staying on